Sirona Biochem Corp. (TSX-V symbol: SBM) (the "Company") held its annual general meeting on June 25, 2009. All agenda items, as outlined in the circular, were approved.
As per the AGM Meeting circular the following matters were to be considered:
Receiving the Company’s audited financial statements for its fiscal year ended October 31, 2008, together with the auditor’s report thereon;
Fixing the number of directors at four;
Electing directors for the ensuing year;
Appointing BDO Dunwoody LLP, Chartered Accountants, as the Company’s auditor for the ensuing year and authorizing the directors to set the auditor’s remuneration;
Considering and if thought fit, approving an ordinary resolution adopting a 2009 incentive stock option plan;
Upon motion, it was resolved that the number of directors of the Company be and is hereby set at four.
Howard Verrico (CEO), Mark Senner (President), Christopher Verrico, and Alex Marazzi, were elected as directors of the Company and to hold office until the next AGM or until their successors are elected or appointed subject to the provisions of the Company’s Articles.
It was further resolved that BDO Dunwoody LLP, Chartered Accountants are appointed as the Company’s auditor to hold office until the next annual general meeting, at a remuneration to be determined by the Board of Directors.
Lastly, it was resolved that the Company adopt a 2009 Stock Option Plan which is subject to approval by the TSX Venture Exchange.
Investors are invited to visit the Sirona Biochem website at: https://www.sironabiochem.com where the AGM meeting minutes will be posted in addition to access to the most recent information about the company and its activities. Alternatively, investors are able to e-mail all questions and correspondence to email@example.com where they can also request to be added to the investor e-mail list to receive all future press releases and updates or call John Dougherty, Corporate Development at 604-641-4466
About the Company:
Sirona Biochem Corp. (TSX-V: SBM) is an emerging biotech company dedicated to the discovery and development of novel drug compounds. The current focus is on treatments for Type II Diabetes and Obesity. SBC has entered into a license agreement with TFChem S.A.R.L., a Drug Discovery company based in Rouen, France. TFChem licenses its technology of fluorinated carbohydrate mimics: GlycoMim®, and products in development to biotech companies. The license agreement with TFChem provides for research and development of new compounds known as S.G.L.T. inhibitors. S.G.L.T. inhibitors are a new and exciting class of compounds which have great promise and potential to treat both diabetes and obesity.
On Behalf of the Board of Directors
Sirona Biochem Corp.
President and Director
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This report contains forward looking statements. Resource estimates, unless specifically noted, are considered speculative. Any and all other resource or reserve estimates are historical in nature, and should not be relied upon. By their nature, forward looking statements involve risk and uncertainties because they relate to events and depend on factors that will or may occur in the future. Actual results may vary depending upon exploration activities, industry production, commodity demand and pricing, currency exchange rates, and, but not limited to, general economic factors. Cautionary Note to US investors: The U.S. Securities and Exchange Commission specifically prohibits the use of certain terms, such as "reserves" unless such figures are based upon actual production or formation tests and can be shown to be economically and legally producible under existing economic and operating conditions.